News
- Author:
- M. Alexander Otto
Publish date: November 2, 2023
A small trial in early breast cancer has reported 100% disease-free survival at 3 years in women who skipped surgery following pathologic complete ...
News
- Author:
- M. Alexander Otto
Publish date: November 1, 2023
Results are similar to cemiplimab, but unlike TV, cemiplimab is not yet approved for the indication.
News
- Author:
- M. Alexander Otto
Publish date: October 26, 2023
With similar results reported for pembrolizumab, a question has arisen about how to incorporate induction chemotherapy and pembrolizumab into a new...
News
- Author:
- M. Alexander Otto
Publish date: October 25, 2023
After decades of stagnation, an almost doubling of life expectancy has set a new bar for the first-line treatment of locally advanced/metastatic ur...
News
- Author:
- M. Alexander Otto
Publish date: October 22, 2023
An FDA decision is expected in January on pembrolizumab with concurrent chemoradiotherapy for the first-line treatment of locally advanced cervical...
News
- Author:
- M. Alexander Otto
Publish date: September 27, 2023
Trial results support “the argument that sentinel node positivity is not, in and of itself, a critical parameter that determines therapeutic plans ...
News
- Author:
- M. Alexander Otto
Publish date: September 14, 2023
After hearing two experts debate the evidence at the SOHO annual meeting, an audience seemed swayed to treat high-risk myeloma patients.
News
- Author:
- M. Alexander Otto
Publish date: September 11, 2023
Newer options are improving management of cytopenic patients.
News
- Author:
- M. Alexander Otto
Publish date: September 8, 2023
“That the AI system was able to match the performance of the average reader in this specialized group of mammogram readers indicates the robustness...
News
- Author:
- M. Alexander Otto
Publish date: September 8, 2023
The goal of ongoing research is to prevent CHIP/CCUS progression in higher-risk patients.
News
- Author:
- M. Alexander Otto
Publish date: August 7, 2023
Adding isatuximab to carfilzomib and dexamethasone creates ‘another effective triplet’ for relapsed/refractory multiple myeloma.
News
- Author:
- M. Alexander Otto
Publish date: July 31, 2023
“Our meta-analysis failed to find a significantly strong association between RFS and OS in RCTs of adjuvant immunotherapy,” the authors concluded.<...
News
- Author:
- M. Alexander Otto
Publish date: July 31, 2023
In the largest look into the issue to date, investigators find that neoadjuvant therapy clears DCIS about half of the time.
News
- Author:
- M. Alexander Otto
Publish date: July 17, 2023
“All reasonable efforts should be made to prevent any treatment interruptions,” including “prophylactic measures to reduce the severity of radiatio...
News
- Author:
- M. Alexander Otto
Publish date: June 28, 2023
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies....